Novo Nordisk and Hims & Hers reached an agreement for Hims to sell Novo’s GLP‑1 weight‑loss and diabetes medicines on its telehealth platform at standard prices and to limit promotion of compounded knockoffs. Novo agreed to drop a patent lawsuit while reserving future rights; Hims will offer patients access to approved formulations and an option to switch existing patients to FDA‑approved products. The deal follows regulatory scrutiny and legal action over compounded GLP‑1 alternatives. Both companies framed the pact as improving patient access to branded, clinically vetted therapies while reducing unsafe compounding practices. Industry observers expect the agreement to influence other telehealth‑pharma disputes and reshape how compounders are managed.